Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elvucitabine in Lamivudine-Resistant Chronic Hepatitis B
NCT00040144Phase 2Terminated
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jul 2002
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of elvucitabine in Chronic Hepatitis B (CHB) (4 arms), sponsored by Alexion Pharmaceuticals. Primary endpoints: Safety and Tolerability at 12 weeks and Antiviral Hepatitis B Virus Activity at 12 weeks. Started Jul 2002; status: terminated.
02
Drugs
elvucitabine
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT00040144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00040144.